{"id":"https://openalex.org/W2610486351","doi":"https://doi.org/10.2147/ott.s134382","title":"Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis","display_name":"Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis","publication_year":2017,"publication_date":"2017-05-01","ids":{"openalex":"https://openalex.org/W2610486351","doi":"https://doi.org/10.2147/ott.s134382","mag":"2610486351","pmid":"https://pubmed.ncbi.nlm.nih.gov/28503070","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5426468"},"language":"en","primary_location":{"id":"doi:10.2147/ott.s134382","doi":"https://doi.org/10.2147/ott.s134382","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ott.s134382","pdf_url":"https://www.dovepress.com/getfile.php?fileID=36355","source":{"id":"https://openalex.org/S120324992","display_name":"OncoTargets and Therapy","issn_l":"1178-6930","issn":["1178-6930"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and Therapy","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=36355","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030327324","display_name":"Sarah Batson","orcid":"https://orcid.org/0009-0006-4062-5648","observed_orcids":["https://orcid.org/0009-0006-4062-5648"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Sarah Batson","raw_affiliation_strings":["DRG Abacus, Bicester, Oxfordshire, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DRG Abacus, Bicester, Oxfordshire, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113776784","display_name":"Stephen Mitchell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephen A Mitchell","raw_affiliation_strings":["DRG Abacus, Bicester, Oxfordshire, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DRG Abacus, Bicester, Oxfordshire, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047443171","display_name":"Ricarda Windisch","orcid":"https://orcid.org/0000-0002-8185-1717","observed_orcids":["https://orcid.org/0000-0002-8185-1717"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Ricarda Windisch","raw_affiliation_strings":["F Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":"https://orcid.org/0000-0002-8185-1717","affiliations":[{"raw_affiliation_string":"F Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079392587","display_name":"Elisabetta Damonte","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Elisabetta Damonte","raw_affiliation_strings":["F Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053361502","display_name":"Veronica C. Munk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Veronica Munk","raw_affiliation_strings":["F Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087391532","display_name":"Noem\u0131\u0301 Reguart","orcid":"https://orcid.org/0000-0001-8190-499X","observed_orcids":["https://orcid.org/0000-0001-8190-499X"]},"institutions":[{"id":"https://openalex.org/I4210160192","display_name":"Consorci Institut D'Investigacions Biomediques August Pi I Sunyer","ror":"https://ror.org/054vayn55","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210115097","https://openalex.org/I4210160192","https://openalex.org/I4387153040","https://openalex.org/I4403928279"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Noemi Reguart","raw_affiliation_strings":["Medical Oncology, Hospital Clinic","Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"],"raw_orcid":"https://orcid.org/0000-0001-8190-499X","affiliations":[{"raw_affiliation_string":"Medical Oncology, Hospital Clinic","institution_ids":[]},{"raw_affiliation_string":"Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain","institution_ids":["https://openalex.org/I4210160192"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5030327324"],"corresponding_institution_ids":[],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":1.4043,"has_fulltext":true,"cited_by_count":49,"citation_normalized_percentile":{"value":0.80865423,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":99},"biblio":{"volume":"Volume 10","issue":null,"first_page":"2473","last_page":"2482"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9610000252723694},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9879999756813049},{"id":"https://openalex.org/keywords/first-line-combination-therapy","display_name":"first-line combination therapy","score":0.8730000257492065},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9509999752044678},{"id":"https://openalex.org/keywords/afatinib","display_name":"afatinib","score":0.7889999747276306},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":1.0},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9010000228881836},{"id":"https://openalex.org/keywords/chemotherapy-comparison","display_name":"chemotherapy comparison","score":0.5830000042915344},{"id":"https://openalex.org/keywords/treatment-heterogeneity","display_name":"treatment effect heterogeneity","score":0.4560000002384186},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.3659999966621399},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.37599998712539673},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.46000000834465027}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7543525695800781},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6493226289749146},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.641605019569397},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.609337329864502},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.6056954264640808},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.5547394752502441},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.5116093754768372},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5014731884002686},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.4945363700389862},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4541539251804352},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.44568055868148804},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.41111618280410767},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4104892611503601},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2732108533382416}],"mesh":[],"locations_count":6,"locations":[{"id":"doi:10.2147/ott.s134382","doi":"https://doi.org/10.2147/ott.s134382","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ott.s134382","pdf_url":"https://www.dovepress.com/getfile.php?fileID=36355","source":{"id":"https://openalex.org/S120324992","display_name":"OncoTargets and Therapy","issn_l":"1178-6930","issn":["1178-6930"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and Therapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4276330","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5426468","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:5426468","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5426468","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Onco Targets Ther","raw_type":"Text"},{"id":"pmid:28503070","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28503070","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and therapy","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:c10b88f499724034ab5456d470bfa306","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/c10b88f499724034ab5456d470bfa306","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"OncoTargets and Therapy, Vol Volume 10, Pp 2473-2482 (2017)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/32711","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/tyrosine-kinase-inhibitor-combination-therapy-in-first-line-treatment--peer-reviewed-article-OTT","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.2147/ott.s134382","doi":"https://doi.org/10.2147/ott.s134382","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ott.s134382","pdf_url":"https://www.dovepress.com/getfile.php?fileID=36355","source":{"id":"https://openalex.org/S120324992","display_name":"OncoTargets and Therapy","issn_l":"1178-6930","issn":["1178-6930"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"},{"display_name":"Meta-Analysis","id":"https://openalex.org/study-designs/meta-analysis"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320309432","display_name":"F. Hoffmann-La Roche","ror":"https://ror.org/00by1q217"},{"id":"https://openalex.org/F4320314458","display_name":"National Comprehensive Cancer Network","ror":"https://ror.org/0465x5x63"},{"id":"https://openalex.org/F4320324142","display_name":"European Society for Medical Oncology","ror":"https://ror.org/03xtz2n86"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2610486351.pdf","grobid_xml":"https://content.openalex.org/works/W2610486351.grobid-xml"},"referenced_works_count":45,"referenced_works":["https://openalex.org/W165173872","https://openalex.org/W1201749067","https://openalex.org/W1480640671","https://openalex.org/W1497402064","https://openalex.org/W1505367831","https://openalex.org/W1906181651","https://openalex.org/W1964238015","https://openalex.org/W1971737397","https://openalex.org/W1974400937","https://openalex.org/W1982967337","https://openalex.org/W2010699829","https://openalex.org/W2017715699","https://openalex.org/W2026951964","https://openalex.org/W2037418758","https://openalex.org/W2060251426","https://openalex.org/W2065350134","https://openalex.org/W2076178766","https://openalex.org/W2096198395","https://openalex.org/W2098301527","https://openalex.org/W2110023367","https://openalex.org/W2110900526","https://openalex.org/W2111662961","https://openalex.org/W2129360604","https://openalex.org/W2132157071","https://openalex.org/W2132870547","https://openalex.org/W2133149289","https://openalex.org/W2136601558","https://openalex.org/W2137046878","https://openalex.org/W2149733252","https://openalex.org/W2150335765","https://openalex.org/W2155338842","https://openalex.org/W2156098321","https://openalex.org/W2160982674","https://openalex.org/W2163351155","https://openalex.org/W2165771694","https://openalex.org/W2171139285","https://openalex.org/W2180488232","https://openalex.org/W2185481272","https://openalex.org/W2210071992","https://openalex.org/W2264348589","https://openalex.org/W2268675562","https://openalex.org/W2339311613","https://openalex.org/W2588751129","https://openalex.org/W2991792334","https://openalex.org/W4241180398"],"related_works":["https://openalex.org/W4389737411","https://openalex.org/W4391135846","https://openalex.org/W2766631446","https://openalex.org/W2906578683","https://openalex.org/W2588751129","https://openalex.org/W3152749268","https://openalex.org/W4292380493","https://openalex.org/W2233607417","https://openalex.org/W4289130231","https://openalex.org/W2999270520"],"abstract_inverted_index":{"Introduction:":[0],"The":[1],"introduction":[2],"of":[3,75,179,258,313],"epidermal":[4,344],"growth":[5,345],"factor":[6,346],"receptor":[7,347],"tyrosine":[8,348],"kinase":[9,349],"inhibitors":[10],"(EGFR-TKIs)":[11],"has":[12],"improved":[13],"the":[14,34,73,117,121,133,195,294,311,314,329],"outlook":[15],"for":[16,167,269,278,284,300],"patients":[17,30,82,171,336],"with":[18,24,33,46,83,172,201,203,222,255,332,337],"advanced":[19,84,338],"non-small-cell":[20,353],"lung":[21,354],"cancer":[22],"(NSCLC)":[23],"EGFR":[25,173,339],"+":[26,174,340],"mutations.":[27],"However,":[28],"most":[29,137],"develop":[31],"resistance,":[32],"result":[35],"that":[36,132,164,317],"median":[37],"progression-free":[38,357],"survival":[39,126,358],"(PFS)":[40],"is":[41,52],"~12":[42],"months.":[43],"Combining":[44],"EGFR-TKIs":[45,80,154],"other":[47],"agents,":[48],"such":[49],"as":[50,289],"bevacizumab,":[51,343],"a":[53,108,149,306,324],"promising":[54,325],"approach":[55,326],"to":[56,68,152,271,320,327],"prolonging":[57],"remission.":[58],"This":[59,213],"systematic":[60],"review":[61],"and":[62,120,128,155,188,240],"network":[63,351],"meta-analysis":[64],"(NMA)":[65],"were":[66,89,100,113,162],"undertaken":[67],"assess":[69],"available":[70],"evidence":[71,283],"regarding":[72],"benefits":[74],"first-line":[76],"combination":[77,214],"therapy":[78,169],"involving":[79],"in":[81,170,198,219,335],"NSCLC.":[85,341],"Methods:":[86],"Literature":[87],"searches":[88],"performed":[90,142],"using":[91,107,115,148],"relevant":[92],"search":[93],"terms.":[94],"Study-level":[95],"pseudo-individual":[96],"patient-level":[97],"data":[98,166,299],"(IPD)":[99],"recreated":[101],"from":[102,262,305],"digitized":[103],"Kaplan\u2013Meier":[104],"curve":[105],"data,":[106],"published":[109],"algorithm.":[110],"Study":[111],"IPD":[112],"analyzed":[114],"both":[116],"proportional":[118],"hazards":[119],"acceleration":[122,145],"failure":[123],"time":[124],"(AFT)":[125],"models,":[127],"it":[129],"was":[130,136,141,281],"concluded":[131],"AFT":[134],"model":[135],"appropriate.":[138],"An":[139],"NMA":[140,315],"based":[143],"on":[144],"factors":[146],"(AFs)":[147],"Bayesian":[150],"framework":[151],"compare":[153],"chemotherapy.":[156],"Results:":[157],"Nine":[158],"randomized":[159],"controlled":[160],"trials":[161],"identified":[163],"provided":[165],"EGFR-TKI":[168,223,250,287,333],"tumors.":[175],"These":[176],"included":[177,293],"studies":[178],"afatinib":[180],"(n=3),":[181,183],"erlotinib":[182,184,301,321],"plus":[185,192,302],"bevacizumab":[186,193,303,319],"(n=1)":[187],"gefitinib":[189,270],"(n=2).":[190],"Erlotinib":[191],"produced":[194,216],"greatest":[196],"increase":[197],"PFS":[199,220,253],"compared":[200,221,254],"chemotherapy,":[202],"1/AF":[204,225,263,272],"being":[205],"0.24":[206],"(95%":[207,229,236,244,265,274],"credible":[208],"interval":[209],"[CrI]":[210],"0.17,":[211],"0.34).":[212],"also":[215],"greater":[217],"increases":[218],"monotherapy:":[224],"versus":[226,233,241],"afatinib,":[227],"0.51":[228],"CrI":[230,237,245,266,275],"0.35,":[231],"0.73);":[232],"erlotinib,":[234],"0.53":[235,264],"0.39,":[238],"0.72)":[239],"gefitinib,":[242],"0.46":[243,273],"0.32,":[246],"0.66).":[247],"All":[248],"three":[249],"monotherapies":[251],"prolonged":[252],"chemotherapy;":[256],"estimates":[257],"treatment":[259],"effect":[260],"ranged":[261],"0.48,":[267],"0.60)":[268],"0.40,":[276],"0.53)":[277],"erlotinib.":[279],"There":[280],"no":[282],"differences":[285],"between":[286],"monotherapies,":[288],"all":[290],"95%":[291],"CrIs":[292],"null":[295],"value.":[296],"Conclusion:":[297],"Although":[298],"came":[304],"single":[307],"Phase":[308],"2":[309],"study,":[310],"results":[312],"suggest":[316],"adding":[318],"may":[322],"be":[323],"improving":[328],"outcomes":[330],"achieved":[331],"monotherapy":[334],"Keywords:":[342],"inhibitor,":[350],"meta-analysis,":[352],"cancer,":[355],"non-squamous,":[356]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":3}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2017-05-12T00:00:00"}